For decades, KRAS was regarded as one of the most challenging targets in oncology due to its high affinity for GTP/GDP and the lack of suitable binding pockets. This perception changed with the discovery of the Switch-II Pocket (S-IIP) in KRAS G12C.

The G12C mutation introduces a cysteine residue at the codon 12, enabling covalent inhibitors to selectively bind and lock KRAS in its inactive GDP-bound state. Based on this mechanism, Sotorasib and Adagrasib achieved meaningful clinical activity in patients with KRAS G12C-mutant non-small cell lung cancer, marking the beginning of the era of direct KRAS inhibition^[1][2].

The success of G12C inhibitors fundamentally changed the perception of KRAS from an "undruggable" target to a clinically actionable oncogenic driver and established the foundation for subsequent KRAS-targeted drug development.

One of the key lessons from the G12C era is that KRAS mutations are not biologically equivalent. Distinct KRAS variants exhibit different frequencies across tumor types and may activate unique downstream signaling programs.

In lung adenocarcinoma (LADC), KRAS G12C is the most prevalent subtype, whereas KRAS G12D and G13D are more commonly observed in pancreatic and colorectal cancers (CRC). Emerging evidence further suggests that specific KRAS mutations may drive distinct biological behaviors and therapeutic responses.

For example, KRAS G13D has been associated with unique HER2-ELF3-KRAS transcriptional regulatory networks in colorectal cancer that are not observed in other KRAS-mutant tumors. These findings indicate KRAS mutations should increasingly be viewed as distinct biological entities rather than a single therapeutic class.

The success of KRAS G12C inhibitors has accelerated a new wave of innovation in KRAS drug discovery. Building on the first proof that direct KRAS inhibition is feasible, current efforts are expanding beyond a single mutation toward broader strategies capable of targeting diverse KRAS variants and RAS-driven cancers.

KRAS G12D is highly prevalent in pancreatic cancer, colorectal cancer and non-small cell lung cancer, yet it has long remained one of the most challenging KRAS mutations to target directly. Unlike KRAS G12C, which introduces a reactive cysteine residue that enables covalent inhibition by agents such as Sotorasib and Adagrasib, the G12D mutation introduces aspartic acid, chemical properties make selective targeting considerably more difficult.

In recent years, however, significant progress has been made in the development of KRAS G12D inhibitors. Several programs have entered clinical evaluation, among which Zoldonrasib and MRTX1133. Notably, Zoldonrasib adopts a RAS(ON) inhibition strategy and can directly engage the activated KRAS G12D. Early clinical studies have demonstrated antitumor activity, highlighting the growing feasibility of targeting this historically challenging mutation.

If G12D inhibitors addresses the needs of specific patient populations, Pan-RAS strategy seek to expand therapeutic coverage cross a much broader spectrum of RAS-driven tumors.

One of the most significant developments in this area came from Daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor capable of targeting multiple KRAS mutation subtypes, including G12D, G12V, G13D, and Q61X. By moving beyond mutation-specific inhibition, Pan-RAS approaches aim to overcome one of the key limitations of first-generation KRAS inhibitors: restricted patient coverage.

At ASCO 2026, results from the Phase III RASolute 302 study demonstrated a median overall survival of 13.2 months in patients with metastatic pancreatic cancer treated with Daraxonrasib, compared with 6.7 months in the chemotherapy group. These findings represent an important milestone in the evolution of RAS-targeted therapy and further support the potential of broader RAS inhibition strategies.

Despite the clinical success of KRAS inhibitors, durable responses remain difficult to achieve. KRAS functions as a central node within multiple interconnected signaling networks, allowing tumor cells to rapidly adapt when KRAS activity is suppressed.

Upon KRAS inhibition, compensatory activation of pathways involving EGFR, SHP2, SOS1, PI3K-AKT, and FGFR, can restore downstream MAPK signaling and sustain tumor growth. Importantly, these adaptive responses often occur before the emergence of secondary resistance mutations, highlighting the remarkable plasticity of KRAS-driven tumors.

The Hippo-YAP pathway is another important downstream effector of KRAS signaling and plays a critical role in regulating cell proliferation, apoptosis, and organ size. In the canonical Hippo pathway, Mst1/2 kinases form a complex with SAV1 to activate Lats1/2 kinase, which subsequently phosphorylate and inhibit the transcriptional co-activators YAP and TAZ. Following dephosphorylation, YAP/TAZ translocate into nucleus, where they interact with transcription factors such as TEAD1-4 to promote cell proliferation and suppress apoptosis.

Beyond their direct effects on tumor cell proliferation, KRAS mutations profoundly influence the surrounding tumor ecosystem. Increasing evidence suggests that oncogenic KRAS actively shapes an immunosuppressive microenvironment that supports tumor progression and limits therapeutic efficacy.

KRAS-driven tumors frequently exhibit elevated expression of immunomodulatory factors such as CXCL8 (IL-8), CXCL1/2/5, and TGF-β, which recruit myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and cancer-associated fibroblasts (CAFs). Together, these components establish a microenvironment that restricts immune-cell infiltration and weakens anti-tumor immunity.

In pancreatic cancer, KRAS-driven fibrotic stroma can account for more than 80% of total tumor volume, creating a substantial barrier to both drug delivery and immune-cell access. These observations suggest that future therapeutic strategies may need to target not only KRAS signaling itself, but also the broader tumor ecosystem that supports disease progression.

Consequently, combining KRAS inhibition with immune modulation, stromal remodeling, or microenvironment-targeted interventions is increasingly viewed as a promising direction for future research.